Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...

NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...

CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs ...

The firm aims to develop siRNAs and antisense oligonucleotides for common diseases that require targeting tissues beyond the liver.

Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...

RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy ...

Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...

An American company with facilities at BioMed Realty's Granta Park in Cambridge has revealed a triple play that could trigger ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Alloy Therapeutics inks multi-target collaboration and license pact with Biogen for use of Alloy’s AntiClastic ASO platform: Boston, Massachusetts Wednesday, April 8, 2026, 16:0 ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...